Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Technology Sector · Franklin Templeton

Franklin Biotechnology Discovery Fund Class R6 (FRBRX)

Ticker FRBRX · · Holdings as of Jul 31, 2026

Expense ratio
0.67%$67/yr per $10k
5-yr return
+6.6%annualized
1-yr return
+52.8%as of Dec 2025
Net assets
$1.2Ball share classes
Holdings
126

Bottom line

Is FRBRX a good fund? The bottom line

FRBRX is the Class R6 share class of Franklin Biotechnology Discovery Fund, a managed technology sector mutual fund from Franklin Templeton.

Its expense ratio is 0.67% — about $67 a year on every $10,000 invested, cheaper than 61% of technology sector funds we track.

It returned +52.8% over one year, +6.6% a year over five years, +7.4% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.2 billion in net assets and 126 holdings, its largest position is Jazz Pharmaceuticals plc (5.7%) and the top 10 make up 36.3% of the portfolio.

What stands out

  • No front-end sales load

Updated Nov 19, 2026

What FRBRX invests in

Capital appreciation.

"Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Funds investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the companys most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such…

From the fund's prospectus (filed Aug 25, 2026).

FRBRX performance

Average annual total returns
1 yr5 yr10 yr
FRBRX+52.8%+6.6%+7.4%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full FRBRX performance history →

What FRBRX costs

On a $10,000 investment, FRBRX's 0.67% expense ratio costs about $67 a year. The prospectus estimates $955 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full FRBRX fee table →

FRBRX top 10 holdings

#Holding% of fund
1Jazz Pharmaceuticals plc5.66%
2Amgen, Inc.4.39%
3Gilead Sciences, Inc.3.86%
4Regeneron Pharmaceuticals, Inc.3.77%
5Argenx SE3.62%
6Vertex Pharmaceuticals, Inc.3.54%
7Franklin Institutional U.S. Government Money Market Fund3.18%
8Revolution Medicines, Inc.3.01%
9Guardant Health, Inc.2.76%
10Ascendis Pharma A/S2.56%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 36.3% of the fund. See all top 25 holdings and asset mix →

Alternatives to FRBRX

More funds like FRBRX →

FRBRX FAQ

What is the expense ratio of FRBRX?
FRBRX's expense ratio is 0.67%, which works out to about $67 a year for every $10,000 invested. The prospectus estimates total costs of $955 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is FRBRX a good investment?
It depends on your goals, but the data points to: no front-end sales load. This is general information, not personalized advice.
What does FRBRX hold?
FRBRX's largest holdings are Jazz Pharmaceuticals plc (5.7%), Amgen, Inc. (4.4%), Gilead Sciences, Inc. (3.9%), Regeneron Pharmaceuticals, Inc. (3.8%), Argenx SE (3.6%). It holds 126 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is FRBRX's 5-year return?
FRBRX returned +6.6% a year over the five years ending Dec 31, 2025, and +7.4% a year over ten years. Past performance does not guarantee future results.
Does FRBRX have a sales load?
No. FRBRX has no front-end sales charge.
Who manages FRBRX?
FRBRX is offered by Franklin Templeton through Franklin Strategic Series.